Research progress on the role of transient receptor potential canonical 6 in ischemia-reperfusion injury
10.3969/j.issn.1674-7445.2022.05.017
- VernacularTitle:瞬时受体电位阳离子通道蛋白6在缺血-再灌注损伤中的作用研究进展
- Author:
Wenwen GUO
1
;
Yuan YUAN
;
Huafeng WEI
;
Hao LUO
;
Lingyu LI
;
Xinghua LYU
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Transient receptor potential canonical 6 (TRPC6);
Ischemia-reperfusion injury;
Ca2+ overload;
Oxidative stress;
Hypericin;
Resveratrol;
Trimetazidine;
Vortioxetine;
Piperazine ferulate
- From:
Organ Transplantation
2022;13(5):659-
- CountryChina
- Language:Chinese
-
Abstract:
Ischemia-reperfusion injury (IRI) refers to the reperfusion injury caused by the recovery of blood supply of ischemic tissues or organs, which commonly occurs in organ transplantation and other surgical procedures. IRI may cause a series of severe clinical issues, such as delayed graft function, acute kidney injury, myocardial infarction, ischemic stroke and circulatory arrest, etc. These events yield high incidence and fatality. At present, no effective solution has been available. Transient receptor potential canonical 6 (TRPC6), a member of Ca2+ channel family, is highly expressed in multiple types of cells. It may adjust many physiological functions by regulating intracellular Ca2+ concentration, which has become an important target for developing therapeutic drugs for multiple diseases. In this article, research progresses on the introduction and function of TRPC6, the association between TRPC6 and IRI and the therapeutic prospect of TRPC6 targeted drugs in IRI were reviewed, aiming to provide novel insights into the prevention and treatment of IRI during organ transplantation
